Back to all news and events
6 February 2017
BioVentrix Announces NUB Reimbursement Status 1 for Revivent TC™ TransCatheter Ventricular Enhancement System in Germany
NUB Status 1 is the highest priority designation available, and was only assigned to a small minority of product submissions for 2017.
2 January 2017
Boston Scientific Closes Acquisition of Neovasc Advanced Biological Tissue Capabilities, Acquires 15% Stake
Boston Scientific Corporation announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, advanced biological tissue business
30 November 2016
RENASCENT-III Trial investigates 100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold
Amaranth Medical announces the trial initiation in Italy and Colombia
June 1, 2016
New ESC Guidelines for Acute and Chronic Heart Failure
On 21 May 2016 the European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) were published in European Heart Journal and the European Journal of Heart Failure. The Guidelines were presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure in Florence, Italy.
May 31, 2016
BioVentrix receives FDA IDE Approval for its Pivotal Clinical Trial, ALIVE
A hybrid closed-chest transcatheter procedure for patients suffering from ischemic cardiomyopathy.
March 30, 2016
Surfacer System rescues obstructed central vein access, first case in Germany
Bluegrass Vascular Technologies, Inc., a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that its Surfacer® Inside-Out® Access Catheter System was successfully used on a patient facing life-threatening complications from end-stage renal disease.